Related Experiment Video

Updated: Mar 25, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

36.1K

Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer

Marco A De Velasco1,2, Yurie Kura1, Kazuhiro Yoshikawa3

  • 1Department of Urology, Kinki University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.

Oncotarget
|February 25, 2016
PubMed

Insights

The pan-AKT inhibitor AZD5363 shows therapeutic potential in PTEN-deficient prostate cancer models. This drug effectively inhibited tumor growth and improved survival in advanced prostate cancer mouse models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The Phosphatidylinositol 3-kinase/AKT (PI3K/AKT) pathway is crucial in prostate cancer development and progression.
  • Loss of phosphatase and tensin homolog (PTEN) function is a common alteration in advanced prostate cancer, leading to PI3K/AKT pathway activation.
  • Targeting the PI3K/AKT pathway offers a promising strategy for personalized prostate cancer therapy.

Purpose of the Study:

  • To evaluate the therapeutic efficacy of the pan-AKT inhibitor AZD5363 in preclinical models of PTEN-deficient prostate cancer.
  • To assess the in vivo pharmacodynamic and antitumor activity of AZD5363 in both castration-naïve and castration-resistant prostate cancer settings.
  • To investigate the impact of AZD5363 on survival and tumor progression in aggressive PTEN/Trp53 (P53) double-deficient prostate cancer models.

Main Methods:

  • Utilized genetically engineered mouse (GEM) models of PTEN-deficient prostate cancer.
  • Administered AZD5363 to evaluate in vivo pharmacodynamic effects on AKT downstream targets.
  • Assessed antitumor activity, including tumor growth inhibition, overall survival, and progression-free survival in various GEM models.

Main Results:

  • AZD5363 demonstrated effective inhibition of AKT signaling pathways in vivo.
  • AZD5363 monotherapy significantly suppressed tumor growth in castration-naïve and castration-resistant PTEN-deficient prostate cancer models.
  • In an aggressive PTEN/P53 double knockout model, AZD5363 significantly delayed tumor progression and improved overall and progression-free survival.

Conclusions:

  • AZD5363 exhibits significant antitumor activity in preclinical models of PTEN-deficient prostate cancer.
  • These findings support the further clinical investigation of AKT-targeting strategies, such as AZD5363, for treating PTEN-deficient prostate cancer.
  • The study provides a strong rationale for developing personalized therapies targeting the PI3K/AKT pathway in advanced prostate cancer.
Keywords:
AKT inhibitorPTENpreclinical modelprostate cancertargeted therapy

More Related Videos

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

9.2K
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

15.3K

Related Concept Videos

Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
6.7K
In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
17.6K